心臓リズム管理デバイスの世界市場 - 2025年～2033年

心臓リズム管理デバイスの世界市場は、2024年に195億3,000万米ドルに達し、2032年には3,269万米ドルに達し、予測期間2025年～2033年のCAGRは6.6%で成長すると予測されています。

心臓リズム管理デバイスは、心臓の機能を監視、調整、サポートするために設計された特殊な医療機器です。これらの機器は、様々な心臓の状態、特に放置すると深刻な健康合併症を引き起こす可能性のある不整脈を管理する上で重要な役割を果たしています。ペースメーカー、除細動器、心臓再同期療法（CRT）の3種類があります。

ペースメーカーは、規則正しい心拍を維持するために心臓に電気インパルスを送る装置です。除細動器は、生命を脅かす不整脈の場合に電気ショックを与えて正常な心臓のリズムを回復させる装置です。CRT装置は、心室の収縮を調整し、心不全患者の効率を向上させます。

この心臓リズム管理デバイス市場を推進する業界の主要企業の製品発表。例えば、2023年10月、ボストン・サイエンティフィック社は、心房細動（AF）、脳梗塞、失神などの疾患に関連する不整脈の長期モニタリング用に設計された次世代デバイス、LUX-Dx II+Insertable Cardiac Monitor（ICM）システムを発売しました。この革新的なシステムは、心臓モニタリングの機能を強化し、高度な技術によって患者ケアの向上を目指しています。これらの要因が、世界の心臓リズム管理デバイス市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

心血管疾患の有病率の上昇

世界の心臓リズム管理デバイス市場の需要は、複数の要因によって牽引されています。心血管疾患（CVDs）の有病率の上昇は、世界の心臓リズム管理（CRM）機器市場の重要な促進要因です。このCVD症例の増加は、効果的なモニタリングと治療ソリューションに対する需要の高まりにつながり、心臓リズム管理デバイス市場の成長と拡大に直接的な影響を与えています。

2023年4月の世界心臓連盟（World Heart Federation）のデータによると、CVDは世界的に死因の第1位となっています。2021年には2,050万人が心血管疾患で死亡しており、これは全世界の死亡者数の約3分の1を占め、1990年に記録されたCVDによる死亡者数1,210万人から大幅に増加しています。心臓に関連する問題と診断される人が増えるにつれ、ヘルスケアプロバイダーはこれらの患者を継続的に監視する効果的なツールを必要とし、ペースメーカー、除細動器、心臓再同期療法（CRT）システムなどの機器の採用が増加しています。

さらに、パートナーシップや提携といった主要企業の戦略は、心臓リズム管理デバイス市場の成長を促進すると思われます。例えば、2024年1月、メドトロニックは、インドでPadma Rhythmsと呼ばれる新しい心臓リズムモニタリング技術を発売し、アクセスを拡大するために、Cardiac Design Labs（CDL）との戦略的パートナーシップを発表しました。この提携は、体外式ループレコーダ（ELR）パッチによる包括的かつ長期的な心臓モニタリングを提供することで、心臓ケアの向上を目指すものです。

また、2023年6月、ロイヤルフィリップスは、心血管・血管内治療に特化した著名な医療機器メーカーであるBIOTRONIK社との提携を発表しました。この提携は、フィリップスのシンフォニースイート顧客に提供可能な心血管機器の範囲を拡大し、オフィスベースのラボ（OBL）や外来手術センター（ASC）のような外来患者ケア環境向けの製品を強化することを目的としています。これらすべての要因が、世界の心臓リズム管理デバイス市場に需要をもたらしています。

さらに、高齢化人口の増加と技術の進歩は、予測期間中に心臓リズム管理デバイス市場を促進すると予想される要因です。

製品リコール

製品リコールは、世界の心臓リズム管理デバイス市場の成長を阻害するでしょう。心臓リズム管理デバイスの世界市場における製品リコール、特に植え込み型除細動器（ICD）や心臓再同期療法除細動器（CRT-D）のリコールは、主にデバイスの誤作動に関連する安全性の懸念によって引き起こされています。

例えば、2023年7月、米国食品医薬品局（FDA）は、メドトロニック社の植込み型除細動器（ICD）および心臓再同期療法除細動器（CRT-D）に重大なリスクがあるとして、クラスIリコールを発表しました。

この誤動作は、短絡保護機能が不適切に作動することにより発生し、生命を脅かす不整脈を修正するために必要なショックを機器が与えることを妨げる可能性があります。これらのリコールは、救命治療のためにこれらの機器に依存している患者にとって深刻な健康リスクにつながる可能性があります。

したがって、上記の要因が心臓リズム管理デバイスの世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の罹患率の上昇
  • 抑制要因
    • 製品リコール
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• ペースメーカー
  • 単腔ペースメーカー
  • デュアルチャンバーペースメーカー
  • 埋め込み型ペースメーカー
• 除細動器
  • 体外式除細動器
  • 植込み型除細動器（ICD）
  • 経静脈ICD（T-ICD）
  • 皮下ICD（S-ICD）
• 心臓再同期療法（CRT）装置
  • CRT-P（ペーシング）
  • CRT-D（除細動）
• その他
• 用途別
• 心不全
• 心房細動
• 心筋梗塞
• 不整脈
• その他

第7章 エンドユーザー別

• 病院と専門クリニック
• ホームケア設定
• 外来手術センター
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Medtronic
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Abbott
• Boston Scientific Corporation
• Biotronik
• Koninklijke Philips N.V.
• Schiller AG
• ZOLL Medical Corporation
• Physio-Control, Inc.（Stryker）
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• GE HealthCare

第11章 付録

The global cardiac rhythm management devices market reached US$ 19.53 billion in 2024 and is expected to reach US$ 32.69 million by 2032, growing at a CAGR of 6.6% during the forecast period 2025-2032.

Cardiac rhythm management devices are specialized medical devices designed to monitor, regulate, and support the functioning of the heart. These devices play a crucial role in managing various heart conditions, particularly arrhythmias, which can lead to serious health complications if left untreated. It is of 3 types: pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) devices.

Pacemakers are devices that deliver electrical impulses to the heart to maintain a regular heartbeat. Defibrillators are devices that provide electric shocks to restore normal heart rhythm in cases of life-threatening arrhythmias. CRT devices help coordinate the contractions of the heart's chambers, improving efficiency in patients with heart failure.

Key players in the industry product launches that would propel this cardiac rhythm management devices market. For instance, in October 2023, Boston Scientific launched the LUX-Dx II+ Insertable Cardiac Monitor (ICM) System, a next-generation device designed for long-term monitoring of arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke, and syncope. This innovative system enhances the capabilities of cardiac monitoring and aims to improve patient care through advanced technology. These factors have driven the global cardiac rhythm management devices market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Cardiovascular Diseases

The demand for the global cardiac rhythm management devices market is driven by multiple factors. The rising prevalence of cardiovascular diseases (CVDs) is a significant driving factor for the global cardiac rhythm management (CRM) devices market. This increase in cases of CVDs leads to a higher demand for effective monitoring and treatment solutions, directly impacting the growth and expansion of the cardiac rhythm management devices market.

According to World Heart Federation data in April 2023, CVDs have been the leading cause of death globally. In 2021, 20.5 million people died from a cardiovascular condition, which accounted for around one-third of all global deaths and was a significant increase from the 12.1 million CVD deaths recorded in 1990. As more individuals are diagnosed with heart-related issues, healthcare providers require effective tools to monitor these patients continuously, leading to an uptick in the adoption of devices like pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) systems.

Furthermore, key players' strategies such as partnerships and collaborations would drive the cardiac rhythm management devices market growth. For instance, in January 2024, Medtronic announced a strategic partnership with Cardiac Design Labs (CDL) to launch and expand access to a novel heart rhythm monitoring technology called Padma Rhythms in India. This collaboration aims to enhance cardiac care by providing comprehensive, long-term heart monitoring through an External Loop Recorder (ELR) patch.

Also, in June 2023, Royal Philips announced a partnership with BIOTRONIK, a prominent medical device company specializing in cardiovascular and endovascular diseases. This collaboration aims to expand the range of cardiovascular devices available for Philips' SymphonySuite customers, enhancing the offerings for outpatient care settings such as office-based labs (OBLs) and ambulatory surgery centers (ASCs). All these factors demand the global cardiac rhythm management devices market.

Moreover, the growing aging population and technological advancements are the factors expected to drive the cardiac rhythm management devices market over the forecast period.

Product recalls

The Product Recalls will hinder the growth of the global cardiac rhythm management devices market. Product recalls in the global cardiac rhythm management devices market, particularly for implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), are primarily driven by safety concerns related to device malfunctions.

For instance, in July 2023, the U.S. Food and Drug Administration (FDA) announced a Class I recall of Medtronic's implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), due to a significant risk associated with these devices.

This malfunction occurs because of inappropriate activation of the short circuit protection feature, which can prevent the device from delivering necessary shocks to correct life-threatening arrhythmias. These recalls can lead to serious health risks for patients who depend on these devices for life-saving therapies.

Thus, the above factors could be limiting the global cardiac rhythm management devices market's potential growth.

Segment Analysis

The global cardiac rhythm management devices market is segmented based on product type, application, end-user, and region.

Product Type:

The cardiac resynchronization therapy (CRT) devices segment is expected to dominate the global cardiac rhythm management devices market share

The cardiac resynchronization therapy (CRT) devices segment holds a major portion of the global cardiac rhythm management devices market share and is expected to continue to hold a significant portion of the global cardiac rhythm management devices market share during the forecast period.

The cardiac resynchronization therapy (CRT) devices segment is expected to hold the largest market share over the forecast period. A CRT device is designed to deliver the issue by sending small electrical impulses to both ventricles. These impulses help the ventricles beat together in a more synchronized pattern, coordinated movement of the fingers and thumb as they flex and curl inward together to form a fist. This synchronization enhances the heart's ability to pump blood more effectively, improving overall cardiac output and ensuring that oxygen and nutrients are delivered efficiently throughout the body.

Cardiac resynchronization therapy (CRT) devices are essential components of the global cardiac rhythm management devices market, particularly in managing heart failure and certain arrhythmias. These devices improve heart contractions, which is crucial for effective cardiac function. The CRT segment is experiencing significant growth owing to multiple factors, including the increasing prevalence of cardiovascular diseases, advancements in technology, and a growing geriatric population.

Furthermore, key players in the industry product launches that would propel this segment's growth in the cardiac rhythm management devices market. For instance, in April 2024, MicroPort CRM launched two new ranges of devices in Europe TALENTIA and ENERGYA. These products include Implantable Cardiac Defibrillators (ICDs) and Cardiac Resynchronization Therapy and Defibrillation devices (CRT-Ds), both featuring advanced Bluetooth connectivity. The integration of Bluetooth technology allows for wireless communication between the devices and healthcare providers. This facilitates tablet-based programming and remote monitoring, improving patient management and follow-up care.

Also, in February 2024, MicroPort CRM announced the launch of two significant products in Japan the GALI SonR Cardiac Resynchronization Therapy and Defibrillation device (CRT-D) and the NAVIGO 4LV left ventricular pacing leads. This launch marks an important advancement in cardiac care technology aimed at improving patient outcomes for individuals with heart rhythm disorders. These factors have solidified the segment's position in the global cardiac rhythm management devices market.

Geographical Analysis

North America is expected to hold a significant position in the global cardiac rhythm management devices market share

The rising incidence of cardiovascular diseases (CVDs), including heart failure, arrhythmias, and coronary artery disease, is a significant driver for the cardiac rhythm management devices market. According to CDC data in October 2024, heart disease is indeed the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. All these factors demand cardiac rhythm management devices.

The increasing burden of cardiovascular diseases (CVDs) is significantly influenced by lifestyle factors such as sedentary behavior, unhealthy dietary habits, and an aging population. As healthcare providers seek advanced technologies to manage these conditions effectively, the cardiac rhythm management (CRM) devices market is poised for substantial growth.

Moreover, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, technological advancements, & investments, and product launches & approvals would propel the cardiac rhythm management devices market growth. For instance, in May 2023, Abbott announced that its Assert-IQ insertable cardiac monitor (ICM) has received clearance from the U.S. Food and Drug Administration (FDA). This new device provides physicians with a robust option for the diagnostic evaluation and long-term monitoring of patients experiencing irregular heartbeats.

Also, in July 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) approved the AVEIR dual chamber (DR) leadless pacemaker system. This innovative device is the world's first dual-chamber leadless pacing system, specifically designed to treat patients with abnormal or slow heart rhythms. Thus, the above factors are expected to drive the cardiac rhythm management (CRM) devices market in the region. Thus, the above factors are consolidating the region's position as a dominant force in the global cardiac rhythm management devices market.

Asia Pacific holds the fastest pace in the global cardiac rhythm management devices market and is expected to hold most of the market share.

The prevalence of cardiovascular conditions, such as arrhythmias and heart failure, is rising in the Asia-Pacific region. This increase is largely attributed to lifestyle changes, urbanization, and an aging population, which collectively heighten the demand for effective cardiac rhythm management solutions. As more individuals are diagnosed with these conditions, the need for advanced devices becomes critical.

The aging demographic in Asia-Pacific countries is particularly susceptible to heart-related issues. As this population segment expands, so does the demand for cardiac devices. Older adults are more likely to experience slow heart rhythms and other cardiovascular diseases, leading to increased healthcare needs and a corresponding rise in device utilization.

Innovations in cardiac device technology, such as leadless pacemakers and remote monitoring systems, are enhancing treatment options and improving patient outcomes. These advancements not only make procedures less invasive but also streamline care delivery, making it more efficient and accessible for patients. Many Asia-Pacific countries are investing significantly in healthcare infrastructure, which facilitates better access to advanced medical technologies. Nations like China and India are expanding their healthcare facilities and services, enabling timely treatment for patients and supporting the adoption of cardiac rhythm management devices.

Furthermore, key players in the region product launches that would drive this global cardiac rhythm management devices market growth. For instance, in November 2024, Abbott launched the AVEIR VR leadless pacemaker in India, specifically designed for patients experiencing slow heart rhythms. This innovative device has received approval from both the Central Drugs Standard Control Organisation (CDSCO) in India and the U.S. Food and Drug Administration (FDA), marking a significant advancement in cardiac care. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global cardiac rhythm management devices market.

Competitive Landscape

The major global players in the cardiac rhythm management devices market include Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Koninklijke Philips N.V., Schiller AG, ZOLL Medical Corporation, Physio-Control, Inc. (Stryker), Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and GE HealthCare among others.

Key Developments

• In March 2024, Abbott received CE mark approval in Europe for its Assert-IQ insertable cardiac monitor (ICM), which is designed for long-term remote monitoring of patients' heart rhythms for up to six years. This device represents a significant advancement in cardiac care technology, enabling healthcare providers to effectively manage patients experiencing irregular heartbeats, including challenging cases such as atrial fibrillation (AF).
• In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICD) and INVICTA defibrillation lead in Japan. This introduction highlights MicroPort's commitment to advancing cardiac care technology and expanding its product offerings in the global market.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cardiac rhythm management devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of cardiovascular diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Product Recalls
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Pacemakers*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Single Chamber Pacemakers
  • 6.2.4. Dual Chamber Pacemakers
  • 6.2.5. Implantable Pacemakers
• 6.3. Defibrillators
  • 6.3.1. External Defibrillators
  • 6.3.2. Implantable Cardioverter Defibrillators (ICD)
  • 6.3.3. Transvenous ICD (T-ICD)
  • 6.3.4. Subcutaneous ICD (S-ICD)
• 6.4. Cardiac Resynchronization Therapy (CRT) Devices
  • 6.4.1. CRT-P (Pacing)
  • 6.4.2. CRT-D (Defibrillation)
• 6.5. Others
• 6.6. By Application
• 6.7. Introduction
  • 6.7.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.7.2. Market Attractiveness Index, By Application
• 6.8. Heart Failure*
  • 6.8.1. Introduction
  • 6.8.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.9. Atrial Fibrillation
• 6.10. Myocardial Infraction
• 6.11. Arrhythmias
• 6.12. Others

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals & Specialty Clinics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Home Care Settings
• 7.4. Ambulatory Surgical Centers
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Medtronic *
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Abbott
• 10.3. Boston Scientific Corporation
• 10.4. Biotronik
• 10.5. Koninklijke Philips N.V.
• 10.6. Schiller AG
• 10.7. ZOLL Medical Corporation
• 10.8. Physio-Control, Inc. (Stryker)
• 10.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 10.10. GE HealthCare

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us